Skip to main content

Summary

Eligibility
for people ages 18 years and up
Location
at San Francisco, California and other locations
Dates
study started
estimated completion:
Principal Investigator

Description

Summary

The purpose of this study is to investigate the PK and safety of NKTR-102 in patients with mild, moderate, or severe hepatic impairment.

Official Title

An Open-Label, Parallel-Group, Multicenter, Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients With Advanced or Metastatic Solid Tumors and Hepatic Impairment

Details

Safety and PK data from patients with mild, moderate, or severe hepatic impairment will be compared with a control group consisting of patients with normal hepatic function.

Keywords

Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

Eligibility

You can join if…

Open to people ages 18 years and up

  • Relapsed or progressive advanced solid tumor malignancies
  • Measurable or non-measurable disease
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Life expectancy greater than 3 months
  • Resolution of all acute toxic effects of prior chemotherapy, and other cancer treatments
  • Adequate bone morrow and kidney function
  • No signs of decompensated liver cirrhosis or ascites requiring therapeutic paracentesis
  • Agree to use adequate contraception

You CAN'T join if...

  • Previous chemotherapy, immunotherapy, chemo-embolization, targeted therapy or investigational agent for malignancy within 4 weeks prior to day 1
  • Cytochrome P450 CYP3A4 inducers and inhibitors within 4 weeks prior to day 1
  • Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing grapefruit or Seville oranges within 14 days prior to day 1
  • UGT1A1 genotype of TA 7 in both alleles (homozygous UGT1A1*28) or TA 8 in either one or both alleles (hetero- or homozygous for UGT1A1*37)
  • Major surgery within 4 weeks prior to day 1
  • Undergone a liver or other organ transplant
  • Concurrent treatment with other anti-cancer therapy
  • Untreated central nervous system metastases
  • Ongoing or active infection
  • Chronic or acute GI disorders resulting in diarrhea
  • Pregnancy or lactation

Locations

  • USC/LA County accepting new patients
    Los Angeles, California, 90089, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Nektar Therapeutics
ID
NCT01991678
Phase
Phase 1
Lead Scientist
Pamela Munster
Study Type
Interventional
Last Updated
March 1, 2017
I’m interested in this study!